Novartis' experimental actinium-225 drug demonstrated significant anti-tumor activity in prostate cancer patients, including ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

Asharq Al Awsat Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...

A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...

MEN taking a common hair loss drug were today warned about the risk of serious psychiatric and sexual side effects. The daily pill finasteride, used by millions worldwide, was already slapped with ...

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several ...